Cover Story
After a courtroom victory against Amgen Inc. this summer, the last of the obstacles was removed for the first biosimilar agent—a white blood cell growth factor—to enter the U.S. market.
In Brief
Drugs & Targets
Trending Stories
- In 1971, Chris Lundy had minute odds of survival. He is now the longest living BMT recipient at the Hutch
- How Beth Carner went from six weeks left to live with stage 4 colon cancer to complete remission
- My bad: I left out Fox Chase
- Edward Copeland, surgeon and breast cancer expert, dies at 86
- NCI creates Cancer Equity Leaders group to improve cancer health equity
- Pooled analysis questions reliability of an endpoint used in multi-cancer detection trials